Biomérieux Posts Strong Third Quarter Sales Growth
Biomérieux reported third quarter organic sales growth that beat expectations, reaching 1.04 billion euros and driven by key strategic plan areas. The French biotechnology firm confirmed its full year guidance while noting a reduced negative currency effect.
Xurve View
Insights:
Xurve View
BIOMERIEUX posted third-quarter sales of €1,042 million ($1.17 billion), beating consensus expectations with an 8% year-on-year increase on Tuesday morning. The revenue beat was driven by a 13% expansion across key growth areas outlined in the company's GO28 strategic plan. France-based Biomérieux outperformed analyst forecasts for organic growth of 5.9%.
